Skip to main content

Table 3 Change in HbA1c levels over 18 months after initiation of second-line treatment

From: Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink

Second-line treatment 6 months 12 months 18 months
N (%) Mean change in HbA1c (SE)* N (%) Mean change in HbA1c (SE)* N (%) Mean change in HbA1c (SE)*
% mmol/mol % mmol/mol % mmol/mol
MET + SU 2257 (50.38) −1.33 (0.04) −14.5 (0.4) 1571 (51.01) −1.30 (0.04) −14.2 (0.4) 907 (51.68) −1.21 (0.05) −13.2 (0.5)
MET + DPP-4i 1486 (33.17) −1.11 (0.04) −12.1 (0.4) 1044 (33.90) −1.12 (0.05) −12.2 (0.5) 572 (32.59) −1.23 (0.06) −13.4 (0.7)
MET + SGLT-2i 225 (5.02) −1.26 (0.08) −13.8 (0.9) 156 (5.06) −1.32 (0.10) −14.4 (1.1) 90 (5.13) −1.46 (0.13) −16.0 (1.4)
Other 512 (11.43) −1.03 (0.06) −11.3 (0.7) 309 (10.03) −1.20 (0.08) −13.1 (0.9) 186 (10.60) −1.18 (0.10) −12.9 (1.1)
Overall 4480 −1.23 (0.03) −13.4 (0.3) 3080 −1.24 (0.04) −13.6 (0.4) 1755 −1.23 (0.05) −13.4 (0.5)
  1. Data from patients who had available HbA1c measurements at each time point and at baseline, and who were on-treatment at each time point (i.e. had not switched, intensified or discontinued second-line treatment since the previous time point)
  2. *Baseline adjusted means using analysis of covariance
  3. Includes all other add-on combinations to metformin, combinations without metformin and other monotherapies
  4. DPP-4i dipeptidyl peptidase-4 inhibitor, MET metformin, SGLT-2i sodium–glucose cotransporter 2 inhibitor, SE standard error, SU sulfonylurea